Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WuXi PharmaTech Invests in $7 Million A Round for Seattle's ApoGen

publication date: Dec 13, 2016
WuXi PharmaTech participated in the $7 million A round of ApoGen Biotechnologies, a Seattle startup targeting drug resistance in cancer cells. ApoGen is focusing on an antiviral component of the human innate immune system – the APOBEC cytidine deaminases – which are enzymes that are implicated in tumor mutations and lead to drug resistance. ApoGen was formed by the Accelerator Corporation of Seattle and New York, a 13-year-old incubator for drug development companies. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital